Abstract
In the ARISTOTLE trial, apixaban, a new oral factor Xa inhibitor, was superior to warfarin for reduction of stroke, mortality, and bleeding rates in patients with atrial fibrillation (JW Cardiol 2011 Aug 29). However, the average time in therapeutic range (TTR) of international normalized ratio (INR) in the warfarin group was low (66%). To compare apixaban and warfarin outcomes in relation to factors affecting TTR, investigators …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
